MA30775B1 - Inhibiteur du recepteur plaquettaire de l'adp - Google Patents

Inhibiteur du recepteur plaquettaire de l'adp

Info

Publication number
MA30775B1
MA30775B1 MA31756A MA31756A MA30775B1 MA 30775 B1 MA30775 B1 MA 30775B1 MA 31756 A MA31756 A MA 31756A MA 31756 A MA31756 A MA 31756A MA 30775 B1 MA30775 B1 MA 30775B1
Authority
MA
Morocco
Prior art keywords
adp
platelet receptor
receptor inhibitor
platelet
severity
Prior art date
Application number
MA31756A
Other languages
English (en)
Inventor
Robert M Scarborough
Shawn M Bauer
Anjali Pandey
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of MA30775B1 publication Critical patent/MA30775B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
    • C07D265/22—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES COMPOSÉS UTILISABLES EN TANT QU'INHIBITEURS DU RÉCEPTEUR PLAQUETTAIRE DE L'ADP DANS LE BUT DE TRAITER UNE THROMBOSE ET DE RÉDUIRE L'ÉVENTUALITÉ ET/OU LA SÉVÉRITÉ D'UN ÉVÉNEMENT ISCHÉMIQUE SECONDAIRE CHEZ UN PATIENT.
MA31756A 2006-09-20 2009-04-02 Inhibiteur du recepteur plaquettaire de l'adp MA30775B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84632806P 2006-09-20 2006-09-20
US11/856,616 US7834023B2 (en) 2006-09-20 2007-09-17 Substituted dihydroquinazolines as platelet ADP receptor inhibitors

Publications (1)

Publication Number Publication Date
MA30775B1 true MA30775B1 (fr) 2009-10-01

Family

ID=39048759

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31756A MA30775B1 (fr) 2006-09-20 2009-04-02 Inhibiteur du recepteur plaquettaire de l'adp

Country Status (16)

Country Link
US (2) US7834023B2 (fr)
EP (1) EP2094272B1 (fr)
JP (1) JP5266232B2 (fr)
KR (1) KR20090057314A (fr)
AU (1) AU2007299723A1 (fr)
BR (1) BRPI0718444A2 (fr)
CA (1) CA2664411A1 (fr)
CO (1) CO6160324A2 (fr)
IL (1) IL197726A0 (fr)
MA (1) MA30775B1 (fr)
MX (1) MX2009003017A (fr)
NO (1) NO20091331L (fr)
NZ (1) NZ576162A (fr)
RU (1) RU2009114827A (fr)
TN (1) TN2009000091A1 (fr)
WO (1) WO2008036843A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100260825A1 (en) * 2009-04-13 2010-10-14 Nair Madhavan G Antifolates for the treatment of cardiovascular, inflammatory, neoplastic, autoimmune and related diseases in sublingual dosage units, film strips, or skin patches
JP2014517074A (ja) 2011-06-24 2014-07-17 アムジエン・インコーポレーテツド Ｔｒｐｍ８アンタゴニストおよび治療におけるそれらの使用
MY157429A (en) 2011-06-24 2016-06-15 Amgen Inc Trpm8 antagonists and their use in treatments
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
US9724351B2 (en) 2012-08-23 2017-08-08 Alios Biopharma, Inc. Compounds for the treatment of paramoxyvirus viral infections
KR20180019234A (ko) 2015-06-26 2018-02-23 다케다 야쿠힌 고교 가부시키가이샤 콜린성 무스카린 m1 수용체의 조절제로서의 2,3-디히드로-4h-1,3-벤족사진-4-온 유도체
JP6787913B2 (ja) 2015-10-20 2020-11-18 武田薬品工業株式会社 複素環化合物
CN117866015A (zh) * 2018-04-30 2024-04-12 联合生物科技公司 一种临床管理中使用的化合物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL135175B2 (en) * 1983-12-22 1985-10-31 Method of printing of articles made of polyamide fibres
DE19650975A1 (de) * 1996-12-09 1998-06-10 Basf Ag Neue heterocyclisch substituierte Benzamide und deren Anwendung
WO2000055153A1 (fr) 1999-03-17 2000-09-21 Astrazeneca Ab Derives amides
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
FR2837201A1 (fr) * 2002-03-18 2003-09-19 Servier Lab Nouveaux composes derives de la quinazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2005097276A (ja) * 2003-08-22 2005-04-14 Takeda Chem Ind Ltd 縮合ピリミジン誘導体およびその用途
WO2005032488A2 (fr) 2003-10-03 2005-04-14 Portola Pharmaceuticals, Inc. Sulfonylurees 2,4-dioxo-3-quinazolinylaryl
JP4879745B2 (ja) * 2003-10-03 2012-02-22 ポートラ ファーマシューティカルズ， インコーポレイテッド 置換イソキノリノン
CA2568756A1 (fr) 2004-06-15 2005-12-29 Astrazeneca Ab Quinazolones substitues en tant qu'agents anticancereux
US20070010537A1 (en) * 2004-08-20 2007-01-11 Kazumasa Hamamura Fused pyramidine derivative and use thereof
NZ554211A (en) 2004-09-29 2010-10-29 Portola Pharm Inc Substituted 2H-1,3-Benzoxazin-4(3H)-ones
JP2009541310A (ja) 2006-06-19 2009-11-26 アストラゼネカ・アクチエボラーグ イソキノリン誘導体およびサイトカイン仲介疾患の阻害剤としてのそれらの使用

Also Published As

Publication number Publication date
US7834023B2 (en) 2010-11-16
CA2664411A1 (fr) 2008-03-27
RU2009114827A (ru) 2010-10-27
TN2009000091A1 (en) 2010-08-19
US20080132499A1 (en) 2008-06-05
HK1131058A1 (en) 2010-01-15
KR20090057314A (ko) 2009-06-04
JP2010504357A (ja) 2010-02-12
NO20091331L (no) 2009-05-20
CO6160324A2 (es) 2010-05-20
WO2008036843A2 (fr) 2008-03-27
IL197726A0 (en) 2009-12-24
EP2094272A2 (fr) 2009-09-02
WO2008036843A3 (fr) 2008-05-15
JP5266232B2 (ja) 2013-08-21
EP2094272B1 (fr) 2014-03-26
AU2007299723A1 (en) 2008-03-27
BRPI0718444A2 (pt) 2013-11-19
NZ576162A (en) 2012-03-30
MX2009003017A (es) 2009-06-08
US20110098247A1 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
MA29639B1 (fr) Derives de cyclohexylamine isoquinolone en tant qu'inhibiteurs de la rhokinase.
MA35460B1 (fr) Composés et compositions en tant qu'inhibiteurs de kinase c-kit
EP1638950A4 (fr) Derives de cyclohexylglycine servant d'inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
EP1978804A4 (fr) Aminocyclohexanes utiles en tant qu'inhibiteurs de la dipeptidyl peptidase-iv pour traiter ou prévenir le diabète
MX2007014616A (es) Inhibidores de señalizacion del receptor del factor a de crecimiento endotelial vascular y del receptor del factor de crecimiento de hepatocitos.
EP2190428A4 (fr) Composés hétérocycliques en tant qu'inhibiteurs de dipeptidylpeptidase-iv pour le traitement ou la prévention des diabètes
EP2054422A4 (fr) Dérivés d'acrylamide en tant qu'inhibiteurs de fab i
EP2063882A4 (fr) Inhibiteurs de kinase pour la prévention ou le traitement d'une infection
MX2008000017A (es) Derivados de isoquinolina como inhibidores de rho-cinasa.
TNSN08039A1 (en) Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors
WO2003105840A3 (fr) Inhibiteurs de sphingosine kinase
MA34969B1 (fr) Composes et compositions en tant qu inibiteurs de trk
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
EA200870424A1 (ru) Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта
MY148902A (en) Substituted isoquinolines and their use as rho-kinase inhibitors
MA33358B1 (fr) Arylpyridine en tant qu'inhibiteurs de l'aldostérone synthase
BRPI0513982A (pt) inibidores de sinalização de receptor de vegf e receptor de hgf
MA31021B1 (fr) Derives de l'isoquinoleine et de l'isoquinoleinone substituees en tant qu'inhibiteurs de la rho-kinase
EP2040713A4 (fr) Dérivés de l'acide biliaire en tant que des ligands de fxr pour la prévention ou le traitement de maladies ou conditions médiées par le fxr
MA32903B1 (fr) Inhibiteurs de proteine-kinases
MA35085B1 (fr) Procede de traitement d'une nephropathie induite par les produits de contraste
ATE394400T1 (de) Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
MX2009003981A (es) Agentes moduladores del receptor de calcio.
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3